1. Date of preparation April 2014 BRI001081ACC.14Annual ScientificSessions of theAmerican College ofCardiologyWashington DC29-31 March 2014

2. Date of preparation April 2014 BRI001081Disclaimer AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) andAstraZeneca Global Policies, and as such will not engage in the promotion ofunregistered products or unapproved indications. These highlights have been suggested by a group of cardiologists who attendedACC.14, compiled by an external medical writer and sponsored by AstraZeneca. Statements of fact and opinions expressed are those of the speakers individually and,unless expressly stated to the contrary, are not the opinion or position of AstraZeneca.AstraZeneca does not endorse or approve, and assumes no responsibility for, thecontent, accuracy, or completeness of the information presented. Presentations areintended for educational purposes only and do not replace independent professionaljudgement. Please refer to the appropriate approved Product Information before prescribing anyagents mentioned in these highlights. 3. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Heart failure clinical trials:Year in reviewCommentary:Associate Professor Rohan RajaratnamLiverpool and Campbelltown Hospitals, Sydney 4. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 5. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 6. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 7. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 8. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 9. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 10. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 11. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 12. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 13. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 14. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 15. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 16. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 17. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 18. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 19. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 20. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 21. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 22. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 23. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 24. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 25. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 26. Commentary:Associate Professor Rohan RajaratnamDate of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 Warfarin continues to have a role in selected patients with heartfailure who are at increased risk of thromboembolism. Comparedto aspirin, it reduces stroke risk without increasing bleeding risk. The role of digoxin in heart failure has declined markedly in theera of modern medications and devices. However, digoxin maybe beneficial in the management of patients with RV dysfunctionsecondary to pulmonary hypertension. It is premature to discarddigoxin completely.